<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952506</url>
  </required_header>
  <id_info>
    <org_study_id>A111_02PK2111P</org_study_id>
    <nct_id>NCT04952506</nct_id>
  </id_info>
  <brief_title>Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dosing, 3-treatment, 6-sequence, 3-period, Crossover-design Pilot Clinical Trial to Compare the Safety and Pharmacokinetics of D113 With CKD-349 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, open-label, single dosing, 3-treatment, 6-sequence, 3-period,&#xD;
      crossover-design study to compare the pharmacokinetics and safety of D113 with CKD-349 in&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of twenty-four (24), following treatments are administered dosing in each&#xD;
      period and wash-out period is a minimum of 7 days.&#xD;
&#xD;
      Reference drug: Entresto 200mg / Test drug: 1) CKD-349 F1 Tab. 2) CKD-349 F2 Tab.&#xD;
&#xD;
      Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics&#xD;
      and safety are assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">August 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-349, D113</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the CKD-349/D113 concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-349, D113</measure>
    <time_frame>Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.33, 1.67, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>The maximum CKD-349/D113 concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference&#xD;
Period 2: Test 1&#xD;
Period 3: Test 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test 2&#xD;
Period 2: Reference&#xD;
Period 3: Test 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test 1&#xD;
Period 2: Test 2&#xD;
Period 3: Reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2-T1-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test 2&#xD;
Period 2: Test 1&#xD;
Period 3: Reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Test 1&#xD;
Period 2: Reference&#xD;
Period 3: Test 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Reference&#xD;
Period 2: Test 2&#xD;
Period 3: Test 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-349 F1 Tab.</intervention_name>
    <description>1T Single does</description>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_label>T2-T1-R</arm_group_label>
    <other_name>Test 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-349 F2 Tab.</intervention_name>
    <description>1T Single does</description>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_label>T2-T1-R</arm_group_label>
    <other_name>Test 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D113 Tab.</intervention_name>
    <description>1T Single does</description>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_label>T2-T1-R</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults over the age of 19 years at the time of screening&#xD;
&#xD;
          2. Individuals who had 18.5 kg/m2 ≤ Body Mass Index(BMI) &lt; 29.9kg/m2 and total body&#xD;
             weight ≥ 55 kg&#xD;
&#xD;
             * BMI = Weight(kg)/ Height(m)2&#xD;
&#xD;
          3. Individuals without congenital/chronic diseases and without abnormal symptoms or&#xD;
             diagnosis based on a medical examination&#xD;
&#xD;
          4. Individuals who were deemed to be appropriate as study subjects following laboratory&#xD;
             tests (hematology, blood chemistry, urinalysis, viral/bacterial, etc.) and vital&#xD;
             signs, ECG etc. performed within 28 days to the scheduled date of first administration&#xD;
             of the investigational product&#xD;
&#xD;
          5. In case of female subjects, those who were confirmed to be non-pregnant at screening&#xD;
&#xD;
          6. Individuals who agreed to the use of appropriate medically recognized contraceptive&#xD;
             methods themselves or their spouse (or partner) from the first administration of the&#xD;
             investigational product to the 7th day of last administration. And in case of male&#xD;
             subjects, those who agreed not donation of sperm, in case of female subjects, those&#xD;
             who agreed not to be pregnant or breast-feeding from the first administration of the&#xD;
             investigational product to the 7th day of last administration&#xD;
&#xD;
          7. Individuals who voluntary decide to participate and agrees in writing to comply with&#xD;
             the precautions after hearing and fully understanding the detailed explanation of this&#xD;
             clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Individuals with a medical evidence or a history of clinically significant&#xD;
             hepatobiliary, renal, neurologic, respiratory, digestive, endocrine, blood-oncology,&#xD;
             urinary, cardiovascular, musculoskeletal or psychiatric&#xD;
&#xD;
          2. Individuals with symptoms of acute disease within 28 days prior to the scheduled date&#xD;
             of first administration of the investigational product&#xD;
&#xD;
          3. Individuals with a medical history of gastrointestinal disease (e.g., Crohn's disease&#xD;
             and ulcer) or gastrectomy (excluding simple appendectomy or herniotomy) that may&#xD;
             affect drug absorption&#xD;
&#xD;
          4. Individuals with a medical history or current symptoms that fall under one or more of&#xD;
             the following who are judged to be concerned about the use of investigational product&#xD;
&#xD;
               -  Individuals with hypersensitivity to investigational products or the&#xD;
                  investigational products ingredients&#xD;
&#xD;
               -  Angiotensin-converting enzyme(ACE) inhibitors are being administered or less than&#xD;
                  36hr after discontinuation.&#xD;
&#xD;
               -  Individuals with history of vascular edema in angiotensin-converting enzyme(ACE)&#xD;
                  inhibitors or angiotensin receptor blocker(ARB) administration&#xD;
&#xD;
               -  Individuals with genetic or idiopathic angioedema&#xD;
&#xD;
               -  Individuals with liver cirrhosis or atresia of bile ducts or cholestasis&#xD;
&#xD;
               -  Individuals with primary hyperaldosteronism&#xD;
&#xD;
          5. Following vital signs results at screening&#xD;
&#xD;
               -  Sitting systolic blood pressure &gt; 140 mmHg or &lt; 90 mmHg&#xD;
&#xD;
               -  Sitting diastolic blood pressure &gt; 90 mmHg or &lt;60 mmHg&#xD;
&#xD;
          6. Individuals with the following results at screening test:&#xD;
&#xD;
               -  AST(GOT) or ALT(GPT) &gt; 2x the upper limit of the normal range&#xD;
&#xD;
               -  Creatinine &gt; upper limit of the normal range or eGFR with MDRD &lt;60 ml/min/1.73 m2&#xD;
&#xD;
               -  K &gt; 5.5mEq/l&#xD;
&#xD;
               -  Positive reaction on serum test(PRP Ab, anti HIV(AIDS), HBs Ag, HCV Ab)&#xD;
&#xD;
          7. Individuals with a medical history of significant drug abuse or positive for abuse&#xD;
             drug in urine test results at screening&#xD;
&#xD;
          8. Individuals who had taken ethical(ETC) or over the counter(OTC) within the 10 days&#xD;
             prior to the first dose of investigational product&#xD;
&#xD;
          9. Individuals who donated whole blood within the 8 weeks, or donated blood components&#xD;
             within 4 weeks prior to the first dose of the investigational product or received a&#xD;
             blood transfusion with 4 weeks&#xD;
&#xD;
         10. Individuals who had been administered investigational product(s) of other clinical&#xD;
             study or bioequivalence study within the 6 months prior to the first dose of this&#xD;
             study&#xD;
&#xD;
         11. Individuals taking medication known to significantly induce or inhibit drug&#xD;
             metabolizing enzymes within 1 month before the first administration of clinical trial&#xD;
             drug&#xD;
&#xD;
         12. Individuals who drunk grapefruit juice or caffeine more than 5 cup per day within 3&#xD;
             months prior to first dose of this study or cannot quit drinking during clinical&#xD;
             trials period&#xD;
&#xD;
         13. A history of regular alcohol consumption exceeding 21 units/week within the 3 months(1&#xD;
             unit = 10 g = 12.5 ml of pure alcohol) prior to screening or individuals who cannot&#xD;
             quit drinking from 48hr prior to the first dose to end of last blooding (1 drink (250&#xD;
             mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL)&#xD;
             of wine (12%) = 12 g)&#xD;
&#xD;
         14. Individuals who exceed the smoking amount of 10 cigarettes per day within 3 months&#xD;
             prior to first dose of this study or cannot quit smoking during clinical trials period&#xD;
&#xD;
         15. Individuals who cannot eat standard meal in institution&#xD;
&#xD;
         16. Individuals who were deemed to be inappropriate to participate in the study by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jang Hee Hong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jang Hee Hong, Professor</last_name>
    <phone>+82-42-280-6940</phone>
    <email>boniii@cnu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-Gyu Jung</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Jang Hee Hong</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

